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Abstract: 
Background - Exome sequencing is a promising tool for gene mapping in Mendelian disorders. 
We utilized this technique in an attempt to identify novel genes underlying monogenic 
dyslipidemias.
Methods and Results - We performed exome sequencing on 213 selected family members from 
41 kindreds with suspected Mendelian inheritance of extreme levels of low-density lipoprotein 
(LDL) cholesterol (after candidate gene sequencing excluded known genetic causes for high 
LDL cholesterol families) or high-density lipoprotein (HDL) cholesterol. We used standard 
analytic approaches to identify candidate variants and also assigned a polygenic score to each 
individual in order to account for their burden of common genetic variants known to influence 
lipid levels.  In nine families, we identified likely pathogenic variants in known lipid genes 
(ABCA1, APOB, APOE, LDLR, LIPA, and PCSK9); however, we were unable to identify 
obvious genetic etiologies in the remaining 32 families despite follow-up analyses.  We 
identified three factors that limited novel gene discovery: (1) imperfect sequencing coverage 
across the exome hid potentially causal variants; (2) large numbers of shared rare alleles within 
families obfuscated causal variant identification; and (3) individuals from 15% of families 
carried a significant burden of common lipid-related alleles, suggesting complex inheritance can 
masquerade as monogenic disease.
Conclusions - We identified the genetic basis of disease in nine of 41 families; however, none of 
these represented novel gene discoveries. Our results highlight the promise and limitations of 
exome sequencing as a discovery technique in suspected monogenic dyslipidemias. Considering 
the confounders identified may inform the design of future exome sequencing studies.  
Key words: genetics, human, DNA sequencing, exome, lipids, exome sequencing, mendelian 
genetics
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Introduction
“Exome” sequencing refers to the use of next generation sequencing (NGS) technology1 to 
sequence all protein-coding regions of the genome.  This approach has emerged as a promising 
tool for gene discovery in families with suspected monogenic disorders2 with some reports 
suggesting a success rate in excess of 50%3. Identifying the genetic basis underlying monogenic 
forms of dyslipidemia has revealed insights into human biology4 and spurred the development of 
novel therapeutics5. In an attempt to map novel dyslipidemia genes, we performed exome 
sequencing on 213 selected family members from 41 kindreds with suspected Mendelian 
inheritance of extreme levels of low-density lipoprotein cholesterol (LDL-C) or high-density 
lipoprotein cholesterol (HDL-C). To enrich for novel gene discoveries, we excluded probands 
from high LDL-C families that had mutations in genes known to cause monogenic 
hypercholesterolemia.
Methods
Subject Recruitment
Forty-one families of European ancestry with suspected Mendelian inheritance of extreme LDL-
C or HDL-C levels were recruited from eight different centers across North America and Europe. 
The pedigrees of these 41 families are shown in Supplementary Figure 1.  Families A1-A9 were 
recruited as part of the French National Research Network on Hypercholesterolemia that 
includes clinicians from 11 different cities in France.  Probands were selected if they met the 
following criteria: total and LDL-C levels above the 95th percentile when compared with a sex- 
and age-matched French population6, triglyceride level below 1.5 mmol/L, and presumed 
autosomal dominant transmission of hypercholesterolemia in the family.  Family A10 was 
recruited from the Preventive Cardiology/Lipid Clinic of the McGill University Health Centre. 
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Affected individuals had LDL-C concentration exceeding the 95th percentile for age- and 
gender-matched subjects, a plasma triglyceride concentration less than 1.0 mmol/L, and no 
known secondary causes of hypercholesterolemia. Families A11-A14 were recruited from the 
Lipid Clinic at the Academic Medical Center, University of Amsterdam, the Netherlands based 
on a clinical diagnosis of familial hypercholesterolemia in the proband. LDL-C levels exceeding 
the 95th percentile when adjusted for age and gender defined affected family members. Families 
A15-A20 were recruited from the Lipid Clinic of the University Hospital of Palermo.  The 
Simon-Broome Register criteria were used to clinically diagnose heterozygous autosomal 
dominant hypercholesterolemia after excluding secondary hypercholesterolemia.  In family A20, 
a pathogenic mutation in LDLR (c.2390-1G/A) was discovered previously but displayed 
incomplete penetrance (Supplementary Figure 1; A20, individuals shaded in black) and was not 
present in the individual with the highest level of LDL-C (the proband III:1 did not carry the 
LDLR mutation and had LDL-C = 455 mg/dL in addition to a history of myocardial infarction at 
the age of 35). Two other subjects (Supplementary Figure 1; A20, individuals shaded in blue) 
also showed high LDL-C and did not have the LDLR mutation. Based on a review of the 
pedigrees (Supplementary Figure 1) an autosomal dominant mode of inheritance was presumed 
for Families A1-A20 with the exception of A13 in which an autosomal recessive mode of 
inheritance was presumed.   
 Families B1 and B2 were recruited from the University Hospital of Palermo and Modena-
Reggio Emilia. Families B3-B12 were recruited from the Washington University Lipid Research 
Clinic.  Affected individuals in these families were identified due to an LDL-C level 
corresponding to the bottom 5th percentile when adjusted for age, ethnicity, and gender. The 
proband (subject III:A) in family B13 was referred to the MGH Lipid Metabolism Unit due to a 
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LDL-C value of 25 mg/dL.  She was noted to have 4 family members with LDL-C values less 
than 47 mg/dL. An autosomal recessive mode of inheritance was presumed for family B1 while 
an autosomal dominant mode of inheritance was presumed for B2-B13 based on the pedigrees 
(Supplementary Figure 1).   
Family C1 was recruited as part of the Genomic Resource in Arteriosclerosis and 
Metabolic Disease at the Cardiovascular Research Institute of the University of California, San 
Francisco. The clinical diagnosis of familial hypoalphalipoproteinemia was based on levels of 
HDL-C below the 5th percentile for five individuals, and below the 10th percentile for one 
individual, when adjusted for age, sex, and the known inverse relationship between TG and 
HDL-C. Family C2 was recruited from the Preventive Cardiology/Lipid Clinic of the McGill 
University Health Centre. Families C3 and C4 were recruited from the outpatient clinic for 
Vascular Medicine at the Academic Medical Center, University of Amsterdam, the Netherlands. 
Affected individuals from families C2-C4 had HDL-C concentration below the 5th percentile for 
age- and gender-matched subjects, a plasma triglyceride concentration less than 1 mmol/L, and 
no known secondary causes of hypoalphalipoproteinemia. An autosomal dominant mode of 
inheritance was presumed for families C1-C4 based on the pedigrees (Supplementary Figure 1).   
 The probands in families D1 and D2 were ascertained from a general patient population 
in the center of The Netherlands and were selected based on having HDL-C levels above the 99th
percentile after adjusting for age and gender7. Family members with HDL-C levels above the 
95th percentile for age- and gender-matched subjects were considered affected.  Families D3 and 
D4 were recruited at the Perelman School of Medicine at the University of Pennsylvania as part 
of a study enrolling individuals with HDL-C levels above the 75th percentile for age-, race-, and 
gender-matched subjects. Spouses and blood relatives of affected individuals were also recruited.  
DOI: 10.1161/CIRCGENETICS.114.000776
7
An autosomal dominant mode of inheritance was presumed for families D1-D4 based on the 
pedigrees (Supplementary Figure 1).   
Causal mutations in LDLR, APOB, and PCSK9 were excluded in the probands of families 
A1-A20 as previously described8, 9.  In addition, causal mutations in LDLRAP1 were excluded in 
the proband from family A13 in which an autosomal recessive mode of inheritance was 
presumed. Candidate gene sequencing was not performed in the other families. 
Replication in Japanese Families
The families shown in Supplementary Figure 6 (Families A-D) were recruited from Kanazawa 
University Hospital in Kanazawa, Japan.  The probands in Families A, C, and D were identified 
due to high LDL-C values and tendinous xanthomas.  An off-treatment LDL-C value was not 
available for the proband in Family B; her LDL-C value was normal, however she was on 
intensive lipid-lowering therapy and was noted to have tendinous xanthomas.  Affected relatives 
in Families A-D had LDL-C values exceeding 200mg/dL. An autosomal dominant mode of 
inheritance was presumed for all four families based on the pedigrees (Supplementary Figure 6).  
All individuals in Families A-D were of self-described Japanese ancestry.
Exome Sequencing
Subsets of samples from each family were selected for exome sequencing based on DNA 
availability, presence of informed consent allowing for genetic studies, and prioritization of 
phenotypic extremes.  These selected samples underwent exome sequencing at the Broad 
Institute.  The IRB at the Broad Institute and all participating sites approved the study protocols 
and all individuals who were selected for sequencing provided informed consent.  Randomly 
sheared genomic DNA was used as input for library construction and in-solution hybrid selection 
to enrich for exomic DNA as previously described10.  In all samples except seven, 33Mb of 
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genomic sequence was defined as the “exome” and targeted using the Whole Exome Agilent 1.1 
plus boosters preparation kit (Agilent Technologies, Santa Clara, CA, USA).  The remaining 
seven samples underwent hybrid selection using a prior version of the Agilent whole exome 
preparation kit that targeted 28.6 Mb of genomic sequence.  Exome-enriched DNA for each 
sample was then sequenced on an Illumina GA-II sequencer using 75-base pair paired-end reads.  
Samples were sequenced with a goal of achieving at least 20-fold coverage in at least 80% of 
??????????????????????????????????????????????????????????????????????????????????????????????
were not used for the primary analysis.
 The Burroughs-Wheeler Alignment algorithm11 was used to map raw sequence reads to 
the human reference sequence (UCSC build HG19).  The Genome Analysis Toolkit (GATK 
version 2)12 and SAMtools13 were used to locally realign reads, recalibrate individual base 
qualities, and flag duplicate sequencing reads for removal.  The GATK UnifiedGenotyper (UG) 
was then used to identify single nucleotide variants and small insertions and deletions in the 
exome target definition specific for each sample along with up to 50 flanking intronic bases.  The 
UG was used in multisample mode and samples were grouped into three batches keeping related 
samples together when possible.  The GATK Variant Score Recalibration tool was used to 
update the quality score of the identified variants and SnpEff14 was used to predict the functional 
consequences of each variant.   The population allele frequency of each variant was estimated 
using the National Heart Lung and Blood Institute’s Exome Sequencing Project (ESP) Exome 
Variant Server (http://evs.gs.washington.edu/EVS).   
Analysis of Exome Sequencing Data 
To exclude genetic variation unlikely to be causal for the extreme phenotype in the affected 
individuals from the families, we employed a heuristic analytical process commonly used in the 
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analysis of exome sequencing studies15.  Starting with the total number of variants shared by 
individuals from the family, we excluded variation that did not fit the expected pattern of 
inheritance based on examining the pedigree.  Next, we excluded common genetic variation, 
?????????????????????????????????????????????????????? extreme excess of very rare alleles in the 
human population16, the exact choice of this threshold – i.e. 1% or 0.01% – has little practical 
impact since most rare alleles within families are well below this threshold).  On the assumption 
that a specific causal variant could not be responsible for both high and low lipid levels, we 
excluded variation present in the affected individuals of the opposite extreme.  Finally, we 
excluded silent and non-genic variation as most Mendelian syndromes are caused by coding or 
splice site mutations that alter the protein sequence17.  The remaining single nucleotide variants 
and short insertions or deletions were considered candidates.  When possible, from this list of 
candidates we attempted to identify variants demonstrating co-segregation with the phenotype in 
the extended kindred.  We considered candidate mutations as causal if (1) the mutation was 
identified in prior publications as causal for the same phenotype; (2) if the mutation was novel 
but in a gene known to cause the phenotype and functionally similar to causal mutations in that 
gene (i.e. a novel nonsense mutation occurring in a gene in which other nonsense mutations have 
been shown to be causal), or (3) if the mutation was novel and occurred in a novel gene but
demonstrated co-segregation with the phenotype in the extended kindred.  The 95% confidence 
intervals (CI) surrounding the success estimates were estimated from the binomial distribution.
Polygenic score analysis 
To determine the likelihood that polygenic inheritance could explain the extreme lipid phenotype 
in some families, individuals with sufficient DNA (n=130) were genotyped on the Illumina 
HumanExome Beadchip v1.0 according to the manufacturer’s recommended protocol.  This 
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genotyping array includes the SNPs reported in the Global Lipids Genetic Consortium (GLGC) 
meta-analysis of genome-wide association studies of plasma lipid levels18.  Of the 102 SNPs 
reported in GLGC Table 1, we successfully genotyped 87 SNPs plus 4 proxies (r2 > 0.9 with the 
GLGC SNP).  Using all 91 SNPs (all SNPs were used for each lipid trait since some of the SNPs 
are associated with more than one lipid fraction), we built baseline polygenic models for the 
LDL-C and HDL-C phenotypes in 9,134 subjects not taking lipid-lowering medications from the 
Ottawa Heart Study19, PROCARDIS20 and the Malmo Diet and Cancer Study21 to obtain 
estimated regression coefficients.  Next, we used the estimated coefficients to obtain a predicted 
lipid level for each individual in our study based on these 91 SNPs.  This predicted lipid level 
was the population mean plus the sum of the individual’s observed genotypes weighted by the 
estimated coefficients. We calculated a residualized phenotype for each individual by subtracting 
the observed lipid level from the predicted lipid level based on the common SNPs.  The observed 
lipid levels were either obtained off treatment or adjusted for lipid-lowering treatment by 
dividing the observed value by 0.7.  Externally standardized residuals were created to assess the 
??????????????????????????????????????????????????????????????????????? ????????????????????????
0.01 (a Bonferroni correction for the average number of individuals sequenced in each family) to 
define a significant residualized score. 
Results
We performed exome sequencing on 213 selected individuals from the 41 families with 
suspected monogenic inheritance of extreme lipid levels, with a median of 4 individuals selected 
per kindred. On average, the mean coverage of targeted bases for each individual was 103.  We 
identified an average of 12,544 nonsynonymous single nucleotide variants and 802 
insertion/deletions per individual.  Within each kindred, we used standard approaches to identify 
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candidate variants15 (Supplementary Figure 2).  In five families (12%), we identified likely 
pathogenic variants (Table 1) in genes previously proven to cause monogenic dyslipidemias 
(“known lipid genes”, Supplementary Table 1).  We also identified the genetic etiology in three 
families after follow-up analysis of their candidate variants (Supplementary Figure 1, Families 
A126, A1030, and A1327) and one after considering the effect of common genetic variants 
(described below), bringing the total to nine (22%; 95% CI [9.3%,34.7%]) (see Table 1 and 
Supplementary Table 2 for details).   
 In the remaining 32 families however, the number of candidate variants ranged from 0-
287, without obvious genetic etiologies despite follow-up analyses.  We sought to understand 
potential reasons for the lack of novel gene discovery and identified three main confounders: 1) 
an inability to identify potentially causal variants due to imperfect sequencing coverage; 2) an 
inability to identify the causal variant among hundreds of shared variants within families; and 3) 
an inability to identify the effect of complex genetics using exome sequencing. 
 To successfully discover a causal variant, the variant must first be identified.  We find 
that despite high average coverage across the exome (on average 89% of targeted bases are 
covered with ???????????????????????????????????????????????????????????????????????????????????
covered across all affected individuals.  Across the known lipid genes we find affected 
?????????????????????????????????????????????????????????????????????????????????????ds (Figure 
1a), a sequencing depth that provides 99% confidence of observing a rare allele at least twice.  
At these positions there is a chance we would fail to identify a variant in the affected individual 
with shallow sequencing coverage and these positions would then be removed from 
consideration under the assumption of complete penetrance without phenocopies.   
Family A1 (Supplementary Figure 1) illustrates this problem. In this family, affected
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individuals were identified to harbor a pathogenic APOE deletion26. Initially, the pathogenic 
deletion (p.Leu167del) was only identified in two of three affected individuals using exome 
sequencing and was thus removed from further consideration.  When orthogonal methods 
(linkage analysis and sequencing under linked peaks) identified p.Leu167del as a candidate, we 
performed Sanger sequencing to confirm the presence of the deletion in all affected individuals.  
This mutation occurs in the last exon of APOE which is difficult to capture and sequence with 
NGS31 and has the lowest coverage and highest GC content of the known lipid genes 
(Supplementary Tables 3 and 4).  The individual in Family A1 initially misclassified by NGS 
only had one sequencing read at that position of the genome.  Across the remainder of the 
e??????????????????????????????????????????????????????????????????????????????????????????????
sequencing reads (Figure 1a). This effect appears to be independent of overall sequencing depth 
(Supplemental Figure 3) suggesting it cannot be solved simply by sequencing to deeper overall 
coverage. It has been previously suggested that exome sequencing fails to identify the genetic 
basis of some strongly inherited conditions due to causal non-coding mutations32; another 
explanation could be that the causal variant is present in the coding region but hitherto 
unidentified. 
 Second, we find a confounding effect from the many rare alleles within families that also 
segregate with the phenotype by chance.  This is highlighted by examining the total number of 
candidate variants even in families harboring pathogenic variants in a known lipid gene.  In these 
families, between 2-346 additional variants remain candidates at the end of the analysis and 
would be considered potentially causal if a pathogenic variant had not been identified.  This is 
similar to the number of variants remaining in families without known genetic causes (range 0-
287; see Figure 1b), highlighting the vast amount of very rare variation “private” to families that  
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segregates with the disease phenotype merely by chance.
Third, we also find that the effect of complex genetics in families with suspected 
monogenic dyslipidemias can be substantial.  Both LDL-C and HDL-C levels are influenced by 
multiple common genetic loci18; we18 and others33 have previously demonstrated that polygenic 
inheritance may be sufficient to explain extreme lipid phenotypes.  To address this possibility in 
the families sequenced in the present study, we genotyped a set of common genetic variants 
robustly associated with lipid traits in genome-wide association studies18.  Using these common 
variants, we created a polygenic score and calculated a residualized phenotypic z-score, 
effectively assigning a level of statistical significance to each individual’s lipid level after 
correcting for that individual’s burden of common lipid-related alleles (Supplementary Figure 4).  
 As a proof-of-principle, we find highly significant scores for individuals from families 
A9 and B2, in which pathogenic PCSK9 and APOB mutations, respectively, perfectly segregate 
with disease status, indicating that common genetic factors are not sufficient to explain the 
phenotype in these families (Supplementary Table 5). In contrast, of the families without a 
readily apparent genetic answer, we find six (15% of all families) where either all affected 
individuals have non-significant scores or only one affected individual retains a significant score, 
suggesting that the burden of common alleles is sufficient to largely explain the extreme 
phenotype in these families (Supplementary Table 6 and Supplementary Figure 5). 
 We also find this approach can help refine phenotypic definitions within families.  In 
Family A7, an initial analysis using clinically-defined affection status (Figure 2a) yielded 17 
candidate variants; additional analyses were unable to identify a causal variant from this list.  
Using the polygenic score, we found individuals III-1 and III-2 had LDL-C levels that were 
largely explained by a burden of common variants whereas individuals II-3 and III-5 had highly 
DOI: 10.1161/CIRCGENETICS.114.000776
14
significant residualized scores (Supplementary Table 7).  An analysis using these updated 
phenotypes identified a candidate variant in LDLR (p.E228K, also known as FH Modena, 
previously shown to be pathogenic28) that was subsequently confirmed to perfectly segregate 
with extreme LDL-C levels in the extended kindred (Figure 2b).  
 We attempted to extend these findings to a non-European population and found similar 
results in families of Japanese descent with extreme LDL-C levels (Supplementary Figure 6).  In 
this analysis a pathogenic variant in LDLR was found in one family (Supplementary Table 8) 
while there was no clear molecular etiology in the remaining three, resulting in a 25% success 
rate.  We found similar levels of imperfect sequence coverage and numbers of rare variants 
segregating within the family (Supplementary Table 9) compared to the families of European 
descent.
Discussion
The present study summarizes our experience using exome sequencing to map novel genes in 
families with a suspected Mendelian dyslipdemia.  After sequencing the exome in 213 
individuals across 41 kindreds, we find this technique identifies a likely causal variant in 22% of 
cases.  Three of these families harbor causal mutations in known lipid genes that were excluded 
by candidate sequencing prior to entry into this study, reconfirming previous results that 
candidate gene sequencing can fail to identify causal mutations in candidate genes that are 
subsequently identified via NGS34.  Notably, we did not identify any novel monogenic 
dyslipidemia genes.  From the remainder of the families in our study, we identify evidence of 
polygenic inheritance in 15%.  We are, however, currently unable to define the genetic basis in 
the remaining 63% of families (Figure 3). 
 Several conclusions emerge from these results. First, from this empiric evaluation, we  
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find the yield of exome sequencing as a tool for novel gene mapping to be modest.  Multiple 
reports detailing the success of this technique have been published since 20092; however, these 
reports may be susceptible to the well-known bias to publish positive results.  Overall, we are 
unaware of reports detailing the overall success rate of exome sequencing.  Our study highlights 
the “real-world” challenges in using this technique for mapping novel genes in Mendelian 
disorders and appears to reflect the collective experience in monogenic dyslipidemias as 
evidenced by the current literature. We are unaware of a Mendelian dyslipidemia gene other than 
ANGPTL335 that has been identified using exome sequencing.  
 Second, we identified several technical issues that have not been previously highlighted 
that adversely impacted our ability to discover novel genes.  An underlying assumption when 
mapping genes with NGS is that all potentially causal variants will be identified. Our study 
reveals some of the limitations of exome sequencing which may be useful to address in future 
design of research or clinical sequencing studies.  
 Third, we find a substantial concerted effect of common lipid-related alleles that appears 
to result in extreme phenotypes in some individuals and families. A similar effect has been 
shown previously for samples drawn from the extremes of the population distribution of plasma 
lipids18 and in a significant proportion of mutation-negative probands who underwent clinical 
genetic testing for familial hypercholesterolemia33. While only approximately 10% of the total 
phenotypic variance in lipid traits is explained by the common variants genotyped in our study18,
by removing this variance we were able to create a more refined phenotype and enrich for 
genetic factors not present in the set of common variants.   We show that incorporating this 
information may inform genetic mapping as we have demonstrated above in Family A7.  
Our study has several limitations. Exome sequencing has limited reliability to identify
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16
large structural variants and while we did consider small insertions and deletions, this technique 
is less reliable in identifying these compared with single nucleotide substitutions.  Reliable 
incorporation of these forms of genetic variation might identify additional candidates36. We also 
did not consider genome-wide linkage data due to the small size of the pedigrees and 
incorporating such information has the potential to reduce the number of candidates37.  From a 
technical perspective, it is possible that other exome capture reagents or sequencing platforms 
(including longer reads) may result in more complete coverage.  Finally, it is important to note 
this experience may not necessarily generalize to other phenotypes.  For example, one might 
expect the yield to be higher for studying extreme syndromic phenotypes less susceptible to the 
influences of polygenic inheritance and environmental factors.  
 Addressing the three problematic areas outlined above has the potential to improve the 
success of gene mapping.  Whole genome sequencing (WGS) could be used to remove the bias 
of target definition and hybrid selection inherent in exome sequencing, although we recognize 
certain portions of the genome will remain recalcitrant to NGS technology38.  The process for 
identifying causal rare alleles within families can be improved as larger population-based 
sequencing studies are performed and as better high-throughput functional assays are developed.  
Sequencing more distantly related relatives can decrease the total number of shared alleles; 
however, investigators typically resort to exome sequencing in small pedigrees for which linkage 
analysis has been intractable. Finally, as we identify additional alleles contributing to complex 
phenotypic traits, we can use these findings to inform family-based genetic studies by both 
selecting families without significant polygenic inheritance and refining phenotypic definitions 
within families. 
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Table 1: Genetic etiologies identified from exome sequencing 
Family 
(Trait) Gene
Genomic 
position*
Reference 
allele
Alternate 
allele Effect 
† Notes
Genetic etiology discovered during initial exome sequencing analysis
A4  
(high LDL) APOB 2:21229554 C T p.A3396T ‡
A9  
(high LDL) PCSK9 1:55509689 T A p.S127R §
B2  
(low LDL) APOB 2:21233022 T A p.K2240* ||
B13  
(low LDL) APOB 2:21229005 - G p.T3579Hfs*34 #
C1
(low HDL) ABCA1 9:107553287 T C p.N1948S **
Genetic etiology discovered from follow-up analysis  
A1  
(high LDL) APOE 19:45412048 CTC - p.L167del ††
A10  
(high LDL) APOE 19:45412048 CTC - p.L167del ††
A13  
(high LDL) LIPA 10:90982268 C T 
Disruption of donor 
splice site ‡‡
Genetic etiology discovered based on phenotypic refinement within the family 
A7  
(high LDL) LDLR 19:11216264 G A p.E228K §§
*Genomic position lists chromosome and position in hg19 coordinates. 
†Effect refers to the predicted protein change using proposed nomenclature22 based on the cDNA sequence with the 
ATG initiation codon numbered p.1. The following reference sequences were used: ABCA1: NM_005502.3, APOB:
NM_000384.2, APOE: NM_000041.2, LDLR: NM_000527.4, PCSK9: NM_174936.3, LIPA: NM_000235.2.
‡To our knowledge this mutation has not been previously identified as causing autosomal dominant 
hypercholesterolemia (ADH). However, this mutation occurs at a highly conserved position within the highly 
conserved LDLR-binding domain of ApoB where other missense mutations causing ADH have been identified. A 
threonine for alanine substitution at this position is computationally predicted to be damaging.
§This mutation has been previously identified as causing ADH in other families5. 
||A report detailing this mutation has been previously published23. 
#To our knowledge this mutation has not been previously identified as causing familial hypobetalipoproteinemia 
(FHBL) however this is expected type of causal mutation for FHBL, inducing a premature truncation of ApoB.
**To our knowledge this mutation has not been previously identified as causing Tangier disease. However, this 
mutation is in the second conserved nucleotide-binding domain (ATP binding cassette) within the Walker A/P-loop 
of ABCA1. It affects the amino acid residue position corresponding to the equivalent Asparagine in the 1st 
nucleotide binding domain which is known to be causal in Tangier disease24,25. The sequences are 
GHNGAGKTTTM (domain 1) and GVNGAGKSSTF (domain 2) (the mutated residue is underlined).
††A report of this mutation causing ADH has been previously published26. 
‡‡A report detailing this mutation has been previously published27. 
§§This mutation, also known as FH-Jerusalem, has been previously identified as causing familial 
hypercholesterolemia28,29. 
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Figure Legends: 
Figure 1: Selected metrics from exome sequencing analysis. (a) Percent targeted bases across 
the exome ????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????? ????????????????????????????????????????
sequencing reads (Green).  (b) Number of candidate variants after analysis for families with a 
suspected pathogenic variant in a gene known to cause monogenic dyslipidemia (orange) 
compared with families without known cause (brown).  P refers to the p-value from the 
Kolmogorov–Smirnov test in testing for differences between the distributions. 
Figure 2:  Pedigree of Family A7, demonstrating the utility of refining phenotypes based on 
burden of common alleles.  (A) Initial pedigree defining affected individuals (shaded) by LDL-C
level adjusted for age and gender. (B) Updated pedigree based on residualized phenotype score 
(see text) where individuals III-1 and III-2 are classified as unaffected. LDLR p.E228K carrier 
status is indicated with + (heterozygous) or - (wild type). The superscript (a) indicates the LDL-
C level was obtained while the individual was on lipid-lowering medication therapy.
Figure 3: Discovery rates from exome sequencing.  The distribution of final discovery status for 
the 41 families with suspected monogenic dyslipidemias that underwent exome sequencing is 
shown with approximate percentages.



